Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Karl Hanf is active.

Publication


Featured researches published by Karl Hanf.


Protein Science | 2006

Affinity enhancement of an in vivo matured therapeutic antibody using structure-based computational design

Louis A. Clark; P. Ann Boriack-Sjodin; John K. Eldredge; Christopher Fitch; Bethany Friedman; Karl Hanf; Matthew Jarpe; Stefano F. Liparoto; You Li; Alexey Lugovskoy; Stephan Miller; Mia Rushe; Woody Sherman; Kenneth J. Simon; Herman W. T. van Vlijmen

Improving the affinity of a high‐affinity protein–protein interaction is a challenging problem that has practical applications in the development of therapeutic biomolecules. We used a combination of structure‐based computational methods to optimize the binding affinity of an antibody fragment to the I‐domain of the integrin VLA1. Despite the already high affinity of the antibody (Kd ∼7 nM) and the moderate resolution (2.8 Å) of the starting crystal structure, the affinity was increased by an order of magnitude primarily through a decrease in the dissociation rate. We determined the crystal structure of a high‐affinity quadruple mutant complex at 2.2 Å. The structure shows that the design makes the predicted contacts. Structural evidence and mutagenesis experiments that probe a hydrogen bond network illustrate the importance of satisfying hydrogen bonding requirements while seeking higher‐affinity mutations. The large and diverse set of interface mutations allowed refinement of the mutant binding affinity prediction protocol and improvement of the single‐mutant success rate. Our results indicate that structure‐based computational design can be successfully applied to further improve the binding of high‐affinity antibodies.


Proteins | 2009

Structural understanding of stabilization patterns in engineered bispecific Ig-like antibody molecules

Jacob L. Jordan; Joseph Arndt; Karl Hanf; Guohui Li; Janine Hall; Stephen J. Demarest; Flora Huang; Xiufeng Wu; Brian Robert Miller; Scott Glaser; Erik J. Fernandez; Deping Wang; Alexey Lugovskoy

Bispecific immunoglobulin‐like antibodies capable of engaging multiple antigens represent a promising new class of therapeutic agents. Engineering of these molecules requires optimization of the molecular properties of one of the domain components. Here, we present a detailed crystallographic and computational characterization of the stabilization patterns in the lymphotoxin‐beta receptor (LTβR) binding Fv domain of an anti‐LTβR/anti‐TNF‐related apoptosis inducing ligand receptor‐2 (TRAIL‐R2) bispecific immunoglobulin‐like antibody. We further describe a new hierarchical structure‐guided approach toward engineering of antibody‐like molecules to enhance their thermal and chemical stability. Proteins 2009.


Archive | 2006

Methods of humanizing immunoglobulin variable regions through rational modification of complementarity determining residues

Alexey Lugovskoy; Karl Hanf; You Li; Kenneth J. Simon; Herman W. T. van Vlijmen


Archive | 2009

Anti-fn14 antibodies and uses thereof

Ellen Garber; Linda C. Burkly; Jennifer S. Michaelson; Alexey Lugovskoy; Yen-Ming Hsu; Karl Hanf


Archive | 2005

Anti-CD154 antibodies

Herman W. T. van Vlijmen; Alexey Alexandrovic Lugovskoy; Karl Hanf


Methods | 2014

Antibody humanization by redesign of complementarity-determining region residues proximate to the acceptor framework

Karl Hanf; Joseph Arndt; Ling Ling Chen; Matthew Jarpe; P. Ann Boriack-Sjodin; You Li; Herman W. T. van Vlijmen; R. Blake Pepinsky; Kenneth J. Simon; Alexey Lugovskoy


Methods of Molecular Biology | 2012

Protein design for diversity of sequences and conformations using dead-end elimination.

Karl Hanf


Archive | 2015

Anticorps anti-alpha v bêta 5 humanisés et leurs utilisations

Thomas Cameron; Michael Adam Crackower; Brian M. Dolinski; Karl Hanf; Amy Theresa Mccurley; Nels E. Pederson; Martin Preyer; Fang Qian; Shelia M. Violette; Paul H. Weinreb


Archive | 2015

HUMANIZED ANTI-ALPHA V BETA 5 ANTIBODIES AND USES THEREOF

Thomas Cameron; Michael Adam Crackower; Brian M. Dolinski; Karl Hanf; Amy Theresa Mccurley; Nels E. Pederson; Martin Preyer; Fang Qian; Shelia M. Violette; Paul H. Weinreb


Archive | 2015

Anticorps anti-gpiib/iiia et leurs utilisations

Joe Salas; Karl Hanf; Der Flier Arjan Van; Bradley R. Pearse

Collaboration


Dive into the Karl Hanf's collaboration.

Researchain Logo
Decentralizing Knowledge